Literature DB >> 7742071

Mouse primary osteoblasts express vitamin D3 25-hydroxylase mRNA and convert 1 alpha-hydroxyvitamin D3 into 1 alpha,25-dihydroxyvitamin D3.

F Ichikawa1, K Sato, M Nanjo, Y Nishii, T Shinki, N Takahashi, T Suda.   

Abstract

We examined whether 1 alpha-hydroxyvitamin D3 (1 alpha(OH)D3) is metabolized into 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25(OH)2D3) in bone. Northern blot analysis indicated that the expression of vitamin D3 25-hydroxylase mRNA was highest in the liver, followed by the duodenum, calvaria, lung, kidney, skin and long bone, and lowest in the spleen. Of the bone cell fractions isolated from fetal mouse calvaria by a sequential enzymatic digestion, fraction 3, which consisted of mostly osteoblastic cells, showed the highest expression of vitamin D3 25-hydroxylase mRNA. When either cultured bone cells of fraction 3 or mouse calvaria were incubated with [3H]-1 alpha (OH)D3, a radioactive peak which comigrated at the same position as authentic 1 alpha,25(OH)2D3 was found on an HPLC chromatogram. The radioactive fraction obtained from the conditioned media of fetal mouse calvaria was tentatively identified as 1 alpha,25(OH)2D3 by cochromatography with authentic 1 alpha,25(OH)2D3 on three different HPLC systems and a thermal isomerization analysis. These results indicate that 1 alpha(OH)D3 is hydroxylated at the 25-position in bones, resulting in the local synthesis of 1 alpha,25(OH)2D3 from 1 alpha(OH)D3 in the skeletal tissues.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742071

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

1.  Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes.

Authors:  M L Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2010-09

2.  Lack of in vitro evidence for storage of 1,25-dihydroxycholecalciferol (1,25(OH)2D3) and 1,25(OH)2D3 binding protein in skeletal matrix.

Authors:  S Boonen; J Aerssens; I Jans; E Van Herck; I Vandewal; J Peeters; R Van den Eynde; J Dequeker; R Bouillon
Journal:  Calcif Tissue Int       Date:  1996-12       Impact factor: 4.333

3.  Fibroblast Growth Factor 23 Regulation by Systemic and Local Osteoblast-Synthesized 1,25-Dihydroxyvitamin D.

Authors:  Loan Nguyen-Yamamoto; Andrew C Karaplis; Rene St-Arnaud; David Goltzman
Journal:  J Am Soc Nephrol       Date:  2016-08-17       Impact factor: 10.121

Review 4.  Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol.

Authors:  Johann D Ringe; Erich Schacht
Journal:  Rheumatol Int       Date:  2004-06-30       Impact factor: 2.631

Review 5.  Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.

Authors:  J D Ringe; E Schacht
Journal:  Rheumatol Int       Date:  2007-08-01       Impact factor: 2.631

Review 6.  Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells.

Authors:  Mariarosaria Negri; Annalisa Gentile; Cristina de Angelis; Tatiana Montò; Roberta Patalano; Annamaria Colao; Rosario Pivonello; Claudia Pivonello
Journal:  Nutrients       Date:  2020-06-17       Impact factor: 5.717

Review 7.  Immune Modulation by Vitamin D and Its Relevance to Food Allergy.

Authors:  Noor H A Suaini; Yuxia Zhang; Peter J Vuillermin; Katrina J Allen; Leonard C Harrison
Journal:  Nutrients       Date:  2015-07-27       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.